TROPHY WAS A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER TRIAL THAT STUDIED THE USE OF TRODELVY
*Assessed using Independent Review Assessment (IRA) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Demographics and patient characteristics (N=112)1
- Median age, years (range): 66 years (33–90 years)
- 78% male; 74% White, 3% Asian, 3% Black, and 20% unknown
- ECOG performance status: 0 (28%), 1 (72%)
- 96% of patients had metastatic disease; 67% of patients had visceral metastases, including 34% with liver metastases
Patients received a median of 3 prior therapies (range: 1–8)1
For 34% of patients, the platinum-containing chemotherapy was received in the neoadjuvant/adjuvant setting only.